According to a research report, INNOVENT BIO (01801) delivered interim results that exceeded expectations, with first-half revenue surging 50.6% to approximately RMB 6 billion, significantly outperforming market expectations. The company's first-half adjusted net profit reached RMB 1.21 billion, already surpassing full-year adjusted net profit forecasts from both analysts and the market.

With the launch of a new product pipeline, the group has adopted a dual-engine growth strategy focusing on oncology treatments and general biomedicine. The company is committed to developing leading pipeline products for the global market and is expected to become a significant participant in the global biopharmaceutical market.

Revenue forecasts for this year have been revised upward to reflect a year-on-year growth of 34.8%, with adjusted earnings forecasts for 2025-27 also updated to reflect stronger-than-expected growth potential. The target price has been raised from HK$110 to HK$120, while maintaining a "buy" rating.